Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$4.59
-0.05-1.08%
At close: -
$4.91
0.326.97%
After Hours: May 23, 9:26 AM EDT
Comments
Loading...
Karyopharm Therapeutics Analyst Ratings and Price Targets | NASDAQ:KPTI | Benzinga
Karyopharm Therapeutics Inc has a consensus price target of $17.8 based on the ratings of 10 analysts. The high is $56 issued by HC Wainwright & Co. on February 26, 2025. The low is $4 issued by Morgan Stanley on August 7, 2023. The 3 most-recent analyst ratings were released by RBC Capital, Barclays, and Baird on May 13, 2025, respectively. With an average price target of $28.33 between RBC Capital, Barclays, and Baird, there's an implied 477.05% upside for Karyopharm Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
RBC Capital
Barclays
Baird
HC Wainwright & Co.
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Karyopharm Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2025 | Buy Now | 572.1% | RBC Capital | Brian Abrahams49% | $34 → $33 | Maintains | Outperform | Get Alert |
| 05/13/2025 | Buy Now | 103.67% | Barclays | Peter Lawson42% | $5 → $10 | Maintains | Overweight | Get Alert |
| 05/13/2025 | Buy Now | 755.4% | Baird | Michael Ulz64% | $54 → $42 | Maintains | Outperform | Get Alert |
| 03/03/2025 | Buy Now | 999.8% | Baird | Michael Ulz64% | $75 → $54 | Maintains | Outperform | Get Alert |
| 02/26/2025 | Buy Now | 1040.53% | HC Wainwright & Co. | Edward White48% | $7 → $56 | Maintains | Buy | Get Alert |
| 02/20/2025 | Buy Now | -38.9% | RBC Capital | Brian Abrahams49% | $3 → $3 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2025 | Buy Now | 42.57% | HC Wainwright & Co. | Edward White48% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 02/10/2025 | Buy Now | -38.9% | RBC Capital | Brian Abrahams49% | $3 → $3 | Reiterates | Outperform → Outperform | Get Alert |
| 01/15/2025 | Buy Now | 42.57% | HC Wainwright & Co. | Edward White48% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2024 | Buy Now | 1.83% | Piper Sandler | Christopher Raymond55% | $4 → $5 | Maintains | Overweight | Get Alert |
| 11/06/2024 | Buy Now | 42.57% | HC Wainwright & Co. | Edward White48% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 11/01/2024 | Buy Now | 42.57% | HC Wainwright & Co. | Edward White48% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | 42.57% | HC Wainwright & Co. | Edward White48% | $7 → $7 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | -38.9% | RBC Capital | Brian Abrahams49% | $3 → $3 | Reiterates | Outperform → Outperform | Get Alert |
| 08/07/2024 | Buy Now | 1.83% | Baird | Mitch Collett41% | $8 → $5 | Maintains | Outperform | Get Alert |
| 06/28/2024 | Buy Now | 42.57% | HC Wainwright & Co. | Edward White48% | $8 → $7 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | 62.93% | HC Wainwright & Co. | Edward White48% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 05/09/2024 | Buy Now | 62.93% | HC Wainwright & Co. | Edward White48% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 62.93% | HC Wainwright & Co. | Edward White48% | $10 → $8 | Maintains | Buy | Get Alert |
| 11/03/2023 | Buy Now | 1.83% | Piper Sandler | Christopher Raymond55% | $7 → $5 | Maintains | Overweight | Get Alert |
| 11/03/2023 | Buy Now | -38.9% | RBC Capital | Brian Abrahams49% | $4 → $3 | Maintains | Outperform | Get Alert |
| 08/07/2023 | Buy Now | -18.53% | Morgan Stanley | Michael Ulz64% | $5 → $4 | Maintains | Equal-Weight | Get Alert |
| 08/03/2023 | Buy Now | 42.57% | Piper Sandler | Christopher Raymond55% | $8 → $7 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | -18.53% | RBC Capital | Brian Abrahams49% | $5 → $4 | Maintains | Outperform | Get Alert |
| 08/03/2023 | Buy Now | 103.67% | HC Wainwright & Co. | Edward White48% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/26/2023 | Buy Now | -18.53% | Wedbush | David Nierengarten61% | $7 → $4 | Maintains | Neutral | Get Alert |
| 07/26/2023 | Buy Now | 103.67% | HC Wainwright & Co. | Edward White48% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 07/18/2023 | Buy Now | 103.67% | HC Wainwright & Co. | Edward White48% | → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/05/2023 | Buy Now | 1.83% | RBC Capital | Brian Abrahams49% | $6 → $5 | Maintains | Outperform | Get Alert |
| 05/05/2023 | Buy Now | 103.67% | HC Wainwright & Co. | Edward White48% | $16 → $10 | Maintains | Buy | Get Alert |
| 05/05/2023 | Buy Now | 103.67% | Baird | Mitch Collett41% | $14 → $10 | Maintains | Outperform | Get Alert |
| 04/19/2023 | Buy Now | 225.87% | HC Wainwright & Co. | Edward White48% | → $16 | Reiterates | → Buy | Get Alert |
| 02/22/2023 | Buy Now | 225.87% | HC Wainwright & Co. | Edward White48% | → $16 | Maintains | Buy | Get Alert |
| 02/16/2023 | Buy Now | 22.2% | RBC Capital | Brian Abrahams49% | $7 → $6 | Maintains | Outperform | Get Alert |
| 02/16/2023 | Buy Now | 225.87% | HC Wainwright & Co. | Edward White48% | → $16 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | 1.83% | Morgan Stanley | Michael Ulz64% | $7 → $5 | Maintains | Equal-Weight | Get Alert |
| 01/19/2023 | Buy Now | 62.93% | Piper Sandler | Christopher Raymond55% | → $8 | Initiates | → Overweight | Get Alert |
| 01/10/2023 | Buy Now | 225.87% | HC Wainwright & Co. | Edward White48% | $18 → $16 | Maintains | Buy | Get Alert |
| 01/10/2023 | Buy Now | 1.83% | SVB Leerink | Jonathan Chang38% | $6 → $5 | Maintains | Market Perform | Get Alert |
| 11/04/2022 | Buy Now | 103.67% | RBC Capital | Brian Abrahams49% | $7 → $10 | Upgrade | Sector Perform → Outperform | Get Alert |
| 11/04/2022 | Buy Now | 22.2% | SVB Leerink | Jonathan Chang38% | $5 → $6 | Maintains | Market Perform | Get Alert |
| 09/09/2022 | Buy Now | 42.57% | Morgan Stanley | Michael Ulz64% | $10 → $7 | Maintains | Equal-Weight | Get Alert |
| 08/05/2022 | Buy Now | 266.6% | HC Wainwright & Co. | Edward White48% | $21 → $18 | Maintains | Buy | Get Alert |
| 08/05/2022 | Buy Now | 185.13% | Baird | Colleen Kusy33% | $17 → $14 | Maintains | Outperform | Get Alert |
| 08/05/2022 | Buy Now | 62.93% | Barclays | Peter Lawson42% | $14 → $8 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Karyopharm Therapeutics (KPTI) stock?
The latest price target for Karyopharm Therapeutics (NASDAQ:KPTI) was reported by RBC Capital on May 13, 2025. The analyst firm set a price target for $33.00 expecting KPTI to rise to within 12 months (a possible 572.10% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Karyopharm Therapeutics (KPTI)?
The latest analyst rating for Karyopharm Therapeutics (NASDAQ:KPTI) was provided by RBC Capital, and Karyopharm Therapeutics maintained their outperform rating.
When was the last upgrade for Karyopharm Therapeutics (KPTI)?
The last upgrade for Karyopharm Therapeutics Inc happened on November 4, 2022 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for Karyopharm Therapeutics Inc.
When was the last downgrade for Karyopharm Therapeutics (KPTI)?
There is no last downgrade for Karyopharm Therapeutics.
When is the next analyst rating going to be posted or updated for Karyopharm Therapeutics (KPTI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karyopharm Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karyopharm Therapeutics was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
Is the Analyst Rating Karyopharm Therapeutics (KPTI) correct?
While ratings are subjective and will change, the latest Karyopharm Therapeutics (KPTI) rating was a maintained with a price target of $34.00 to $33.00. The current price Karyopharm Therapeutics (KPTI) is trading at is $4.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
